The potential impact of azithromycin in idiopathic pulmonary fibrosis
- PMID: 30442715
- DOI: 10.1183/13993003.00628-2018
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Conflict of interest statement
Conflict of interest: C. Macaluso has nothing to disclose. Conflict of interest: J. Maritano Furcada has nothing to disclose. Conflict of interest: O. Alzaher has nothing to disclose. Conflict of interest: R. Chaube has nothing to disclose. Conflict of interest: F. Chua has nothing to disclose. Conflict of interest: A.U. Wells reports speaker's and consultancy fees from Intermune Roche, Boehringer Ingelheim and Bayer. Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB, and has received consultancy or speaker's fees from Apellis, AstraZeneca, aTyr Pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche, Sanumed and UCB. Conflict of interest: P.M. George reports receiving honoraria and speaker's fees from Roche Pharmaceuticals and Boehringer Ingelheim, outside the submitted work. Conflict of interest: E.A. Renzoni has received speaker's fees from Boehringer Ingelheim, Roche and Mundipharma. Conflict of interest: P.L. Molyneaux has nothing to disclose.
Similar articles
-
Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis.Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):242-246. Sarcoidosis Vasc Diffuse Lung Dis. 2016. PMID: 27758989
-
Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study.BMC Pulm Med. 2017 Jun 19;17(1):94. doi: 10.1186/s12890-017-0437-z. BMC Pulm Med. 2017. PMID: 28629448 Free PMC article.
-
Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.Am J Respir Crit Care Med. 2019 Oct 1;200(7):857-868. doi: 10.1164/rccm.201901-0094OC. Am J Respir Crit Care Med. 2019. PMID: 31046405 Clinical Trial.
-
Macrolide antibiotics for cystic fibrosis.Cochrane Database Syst Rev. 2011 Dec 7;(12):CD002203. doi: 10.1002/14651858.CD002203.pub3. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2012 Nov 14;11:CD002203. doi: 10.1002/14651858.CD002203.pub4. PMID: 22161368 Updated. Review.
-
Antibiotic prevention of acute exacerbations of COPD.N Engl J Med. 2012 Jul 26;367(4):340-7. doi: 10.1056/NEJMct1115170. N Engl J Med. 2012. PMID: 22830464 Review. No abstract available.
Cited by
-
Azithromycin targets the CD27 pathway to modulate CD27hi T-lymphocyte expansion and type-1 effector phenotype.Front Immunol. 2024 Aug 15;15:1447625. doi: 10.3389/fimmu.2024.1447625. eCollection 2024. Front Immunol. 2024. PMID: 39211048 Free PMC article.
-
The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.Transl Lung Cancer Res. 2022 Mar;11(3):472-496. doi: 10.21037/tlcr-21-880. Transl Lung Cancer Res. 2022. PMID: 35399571 Free PMC article. Review.
-
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.Int J Mol Sci. 2022 Jan 17;23(2):977. doi: 10.3390/ijms23020977. Int J Mol Sci. 2022. PMID: 35055163 Free PMC article. Review.
-
Management of Fibrosing Interstitial Lung Diseases.Adv Ther. 2019 Jul;36(7):1518-1531. doi: 10.1007/s12325-019-00992-9. Epub 2019 May 22. Adv Ther. 2019. PMID: 31119691 Free PMC article. Review.
-
Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis.ERJ Open Res. 2023 May 22;9(3):00720-2022. doi: 10.1183/23120541.00720-2022. eCollection 2023 May. ERJ Open Res. 2023. PMID: 37228285 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
